Association of tumor necrosis factor–α (G-308A) genetic variant with matrix metalloproteinase–9 activity and joint destruction in early rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Rheumatology

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10067-017-3699-1PMID 28573370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis

  2017cited by this paper
• Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

  2016cited by this paper
• [New assessment method in rheumatoid arthritis].

  2016cited by this paper
• Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

  2014cited by this paper
• Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

  2014cited by this paper
• Moving towards personalized medicine in rheumatoid arthritis

  2014cited by this paper
• Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis

  2011cited by this paper
• Rheumatoid arthritis

  2010cited by this paper
• Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype

  2010cited by this paper
• Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis

  2009cited by this paper
• Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects

  2008cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

  2008cited by this paper
• The −308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients

  2007cited by this paper
• A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis

  2007cited by this paper
• The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.

  2007cited by this paper
• Matrix metalloproteinases: role in arthritis.

  2006cited by this paper
• Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α

  2006cited by this paper
• Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.

  2006cited by this paper
• Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis

  2006cited by this paper
• MAP Kinase activation is required for the MMP-9 induction by TNF-stimulation

  2005cited by this paper
• MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis

  2005cited by this paper
• Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study

  2005cited by this paper
• TNF-alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production.

  2005cited by this paper
• Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis

  2003cited by this paper
• Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

  2003cited by this paper
• Involvement of apoptotic cell death in autoimmune diseases

  2002cited by this paper
• Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression.

  1998cited by this paper
• Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis.

  1998cited by this paper
• Polymorphism of the tumour necrosis factor‐alpha and lymphotoxin‐alpha genes in chronic lymphocytic leukaemia

  1997cited by this paper
• Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.

  1996cited by this paper
• How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies.

  1995cited by this paper
• Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1.

  1993cited by this paper

• Identification of Hedyotis diffusa Willd-specific mRNA–miRNA–lncRNA network in rheumatoid arthritis based on network pharmacology, bioinformatics analysis, and experimental verification

  2024cites this paper
• Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast‐like synoviocytes by liver X receptors

  2024cites this paper
• Matrix Metalloproteinase-9 Level in Synovial Fluid—Association with Joint Destruction in Early Rheumatoid Arthritis

  2023cites this paper
• Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients

  2021cites this paper
• Effects of All-Trans Retinoic Acid on the Optimization of Synovial Explant Induced by Tumor Necrosis Factor Alpha.

  2020cites this paper
• Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast‐like synoviocytes by blocking activation of the MAPK pathway

  2018cites this paper
• Association of the A Allele of the TNF-Alpha-308 G/A Gene Polymorphism with Radiographic Progression in Rheumatoid Arthritis

  2018cites this paper
• Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines

  2018cites this paper
• One year in review 2018: pathogenesis of rheumatoid arthritis.

  2018cites this paper
• Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

  2018cites this paper
• Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.

  2018cites this paper